“Startups usually launch their products first in wealthy countries. Launching first in an emerging market is seen as a nonstarter because of commercial, regulatory, and political risks. This is starting to change: Pricewaterhousecoopers recently reported that faster approvals overseas are encouraging startups to enter the U.S. market last in some cases.
Consider Diagnostics for All, a Boston-area startup developing paper-based diagnostic tests the size of a postage stamp. Miniature wells patterned onto the paper contain chemicals that react with samples of blood, urine, saliva, or sweat, which causes the paper to display a reading with a change of color.
The technology is revolutionary because the paper tests can be manufactured for only a few cents and can deliver test results instantaneously. By contrast, existing diagnostic machines sold by multinationals cost over $20 per test and $30,000 for the test reader, require trained technicians, and take three hours to yield results. Even in wealthy countries, community hospitals and rural clinics can’t afford them. . .” Full Story on Harvard Business Review